Response to the letter to the editor entitled 'Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic'.

We thank Drs Kow and Hasan [1] for their comments about our review on the role of angiotensin receptor blockers (ARBs) in cardiovascular disease (CVD) risk management [2]. Drs Kow and Hasan [1] pre...